JPMorgan analyst Zain Ebrahim raised the firm’s price target on Genmab (GMAB) to DKK 2,050 from DKK 1,650 and keeps a Neutral rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab announces data from two trials on epcoritamab-bysp
- Genmab announces primary data from Phase 3 EPCORE FL-1 study
- Genmab A/S Discloses Managerial Share Transactions as of December 1, 2025
- Genmab A/S: Promising Growth Prospects with Strategic Catalysts and Robust Pipeline
- Genmab A/S Updates Articles of Association for Financial Flexibility